BidaskClub Upgrades Arvinas (NASDAQ:ARVN) to Sell

Arvinas (NASDAQ:ARVN) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday, BidAskClub reports.

A number of other brokerages have also commented on ARVN. Zacks Investment Research lowered Arvinas from a “hold” rating to a “sell” rating in a research report on Thursday, August 6th. Oppenheimer initiated coverage on Arvinas in a research report on Tuesday, August 4th. They issued a “hold” rating on the stock. Citigroup upgraded Arvinas from a “neutral” rating to a “buy” rating and set a $45.00 price objective on the stock in a research report on Monday, June 1st. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 price target on shares of Arvinas in a research report on Friday, May 29th. Finally, ValuEngine raised Arvinas from a “hold” rating to a “buy” rating in a research note on Friday, August 28th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. Arvinas has a consensus rating of “Buy” and an average price target of $55.18.

Shares of ARVN opened at $27.35 on Tuesday. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -11.84 and a beta of 1.45. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.40 and a current ratio of 7.40. The business’s fifty day moving average price is $27.07 and its two-hundred day moving average price is $37.56. Arvinas has a 52 week low of $15.19 and a 52 week high of $61.57.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.06). Arvinas had a negative net margin of 182.59% and a negative return on equity of 31.68%. As a group, research analysts forecast that Arvinas will post -2.57 EPS for the current year.

In other Arvinas news, insider Ronald Peck sold 1,256 shares of Arvinas stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $27.46, for a total transaction of $34,489.76. Following the transaction, the insider now directly owns 4,010 shares in the company, valued at $110,114.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 10.99% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. FMR LLC lifted its stake in Arvinas by 41.5% in the second quarter. FMR LLC now owns 3,824,462 shares of the company’s stock valued at $128,272,000 after buying an additional 1,122,563 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Arvinas by 24.6% during the second quarter. Bellevue Group AG now owns 1,581,703 shares of the company’s stock worth $53,051,000 after acquiring an additional 312,400 shares during the period. Vanguard Group Inc. lifted its position in Arvinas by 19.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,098,362 shares of the company’s stock valued at $36,839,000 after acquiring an additional 176,150 shares in the last quarter. Avidity Partners Management LP acquired a new position in Arvinas in the 2nd quarter worth $36,119,000. Finally, State Street Corp increased its holdings in Arvinas by 7.8% during the 1st quarter. State Street Corp now owns 473,004 shares of the company’s stock worth $19,062,000 after purchasing an additional 34,356 shares in the last quarter. Hedge funds and other institutional investors own 92.51% of the company’s stock.

About Arvinas

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Further Reading: Why is the LIBOR significant?

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.